CPT1A and fatty liver disease: In a previous evidence, metformin reversed hepatic steatosis by blocking ACC via AMPK activation which subsequently minimized build-up of malonyl-CoA (inhibitor of CPT1), therefore, upregulating hepatic oxidation of fatty acids (FAO) [37].